Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
RAPT Therapeutics Inc
RAPTCurrent price
1.28 USD
-0.29 USD (-18.47%)
Last closed
1.74 USD
Company
www.rapt.com
ISIN
US75382E1091
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
100 871 120 USD
Yield for 12 month
-89.35 %
1Y
3Y
5Y
10Y
15Y
RAPT
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Address: 561 Eccles Avenue, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
8 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+1 527 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-3 551 000 USD
Last Year
+1 527 000 USD
Current Quarter
-305 000 USD
Last Quarter
-314 000 USD
Key Figures RAPT
1 year
3 years
5 years
10 years
EBITDA
-127 717 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-46.34 %
PEG Ratio
–
Return On Equity TTM
-77.98 %
Wall Street Target Price
8 USD
Revenue TTM
–
Book Value
3.13 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100 %
Dividend Yield
–
Gross Profit TTM
1 527 000 USD
Earnings per share
-3.13 USD
Diluted Eps TTM
-3.13 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics RAPT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RAPT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation RAPT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
677.3673
Price Sales TTM
411.2189
Enterprise Value EBITDA
-10.7294
Price Book MRQ
0.9236
Financials RAPT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RAPT
For 52 weeks
1.31 USD
27.35 USD
50 Day MA
1.98 USD
Shares Short Prior Month
3 139 136
200 Day MA
6.18 USD
Short Ratio
11.13
Shares Short
2 866 510
Short Percent
11.04 %
BeatStart